peoplePerson
Clemens Kratochwil
Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.
Clemens Kratochwil published the first clinical experience with 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer, launching the alpha-emitter era in prostate cancer.
Role
Nuclear medicine physician, Heidelberg University Hospital
Institution
Specialisms
Targeted alpha therapyPSMA radioligandsDosimetry
Profiles
| Title | Journal | Year |
|---|---|---|
| 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer | Journal of Nuclear Medicine | 2016 |